2025.06.29本文字数:1245,阅读时长大约3.2分钟导读:6月26日,上海迈威生物将新获批长效升白药阿格司亭α的销售权转让给齐鲁制药,交易额达5亿元。齐鲁制药在升白针市场面临石药、恒瑞的夹击,急需新药巩固地位,此次交易助力其市场突破。6月26日,上海迈威生物发布消息,宣布将其新获批的长效升白药物——注射用阿格司亭α的销售权转让给齐鲁制药,交易总金额为5亿元人民币。其中,首付款高达3.8...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.